Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

This study has been terminated.
Information provided by:
Nantes University Hospital Identifier:
First received: June 14, 2006
Last updated: June 15, 2006
Last verified: August 2004

June 14, 2006
June 15, 2006
August 2003
Not Provided
  • Complete remission after 4 cycles:
  • disappearance of serum and/or urine M-component (confirmed by immunofixation)
  • < 5% plasma cells in the bone marrow resolution of all extra-osseous plasmacytomas
  • no evidence of bone progression
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
A Multicenter Open-Label Phase II Study of Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
The objective of this study is to evaluate the efficacy and safety of Velcade plus dexamethasone used as induction chemotherapy prior to autologous transplantation.
Not Provided
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Multiple Myeloma
  • Drug: Dexamethasone
  • Drug: velcade
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided

Inclusion Criteria:

  • diagnosis of MM according to the SWOG criteria (annex 1)
  • previously untreated (localized radiotherapy is allowed)
  • symptomatic MM stage II or III according to Durie-Salmon staging system (annex 2) or stage I with one symptomatic osteolytic lesion
  • with measurable levels of paraprotein in the serum (> 1g/dl) or in the urine (> 0.2g/24h)
  • age < 75 years
  • able to understand and to given an informed consent
  • male, female without childbearing potential or negative urine pregnancy test within 72 hours prior to beginning the treatment. Women of childbearing potential must be following adequate contraceptive measures.
  • no active systemic infection. In the presence of any active systemic infection, adequate broad-spectrum or organism-specific antibiotic coverage must be administered. Patients must be a febrile with stable vital signs while receiving antibiotics for at least 48 hours prior to beginning the treatment with Velcade plus dexamethasone.

Exclusion Criteria:

  • life expectancy < 2 months
  • ECOG performance status > 2 (annex 3)
  • proven amyloidosis
  • positive HIV serology
  • antecedents of severe psychiatric disease
  • severe diabetes contraindicating the use of high-dose corticoïds
  • > NCI grade 2 peripheral neuropathy (Annex IV)
  • serum biochemical values as follow

    • creatinin level > 200mmol/l
    • bilirubin, transaminases or gGT > 3 the upper normal limit
  • use of any experimental drugs within 30 days of baseline
18 Years to 75 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
BRD 03/6-E
Not Provided
Not Provided
Not Provided
Not Provided
Nantes University Hospital
Not Provided
Principal Investigator: Jean-Luc HAROUSSEAU, MD NANTES UH
Nantes University Hospital
August 2004

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP